• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Acquired pure red cell aplasia: updated review of treatment.获得性纯红细胞再生障碍性贫血:治疗的最新综述
Br J Haematol. 2008 Aug;142(4):505-14. doi: 10.1111/j.1365-2141.2008.07216.x. Epub 2008 May 28.
2
Diagnosis and management of acquired pure red cell aplasia.获得性纯红细胞再生障碍性贫血的诊断与管理
Hematol Oncol Clin North Am. 2009 Apr;23(2):249-59. doi: 10.1016/j.hoc.2009.01.009.
3
Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.接受环孢素A治疗的获得性原发性特发性纯红细胞再生障碍性贫血患者的长期预后。日本针对纯红细胞再生障碍性贫血协作研究组开展的一项全国性队列研究。
Haematologica. 2007 Aug;92(8):1021-8. doi: 10.3324/haematol.11192. Epub 2007 Jul 20.
4
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.阿仑单抗诱导治疗抵抗性纯红细胞再生障碍完全缓解。
Leuk Res. 2005 Oct;29(10):1213-5. doi: 10.1016/j.leukres.2005.02.018. Epub 2005 Apr 25.
5
Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.100 例纯红细胞再生障碍性贫血成年患者的临床特征和结局。
Ann Hematol. 2022 Jul;101(7):1493-1498. doi: 10.1007/s00277-022-04847-2. Epub 2022 Apr 23.
6
[Progress in the clinical management of pure red cell aplasia and future prospects].[纯红细胞再生障碍性贫血的临床管理进展与未来展望]
Rinsho Ketsueki. 2016 Feb;57(2):110-6. doi: 10.11406/rinketsu.57.110.
7
Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).使用抗CD52单克隆抗体阿仑单抗(Campath-1H)成功治疗与淋巴增殖性疾病相关的难治性纯红细胞再生障碍性贫血。
Br J Haematol. 2003 Oct;123(2):278-81. doi: 10.1046/j.1365-2141.2003.04609.x.
8
[Diagnosis and management of pure red cell aplasia].[纯红细胞再生障碍性贫血的诊断与管理]
Rinsho Ketsueki. 2015 Oct;56(10):1922-31. doi: 10.11406/rinketsu.56.1922.
9
Chronic lymphocytic leukemia-associated pure red cell aplasia.慢性淋巴细胞白血病相关的纯红细胞再生障碍性贫血
Int J Immunopathol Pharmacol. 2009 Apr-Jun;22(2):279-86. doi: 10.1177/039463200902200204.
10
[Pure red cell aplasia of the bone marrow in combination with thymoma. A literature review and own data].[骨髓纯红细胞再生障碍合并胸腺瘤。文献综述及自身数据]
Ter Arkh. 2019 Jul 15;91(7):121-126. doi: 10.26442/00403660.2019.07.000326.

引用本文的文献

1
Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.单克隆丙种球蛋白病相关难治性纯红细胞再生障碍性贫血患者的抗浆细胞治疗:三例报告及文献综述
Ann Hematol. 2025 Aug 21. doi: 10.1007/s00277-025-06565-x.
2
Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.硼替佐米联合地塞米松治疗难治性/复发性纯红细胞再生障碍性贫血患者的无治疗生存期:一项前瞻性临床研究。
Ann Med. 2025 Dec;57(1):2540016. doi: 10.1080/07853890.2025.2540016. Epub 2025 Aug 7.
3
Spectrum of Pure Red Cell Aplasia in a Tertiary Care Hospital in Northeast India.印度东北部一家三级护理医院的纯红细胞再生障碍性贫血谱系
Cureus. 2025 Feb 20;17(2):e79364. doi: 10.7759/cureus.79364. eCollection 2025 Feb.
4
Efficacy and influencing factors of immunosuppressive therapy for pure red cell aplasia: meta-analysis and systematic review.纯红细胞再生障碍性贫血免疫抑制治疗的疗效及影响因素:荟萃分析与系统评价
Ann Hematol. 2025 Apr;104(4):2189-2206. doi: 10.1007/s00277-025-06315-z. Epub 2025 Mar 19.
5
Successful Management of Post-Thymectomy Pure Red Cell Aplasia with Rituximab: A Case Report.利妥昔单抗成功治疗胸腺切除术后纯红细胞再生障碍性贫血:一例报告
Case Rep Oncol. 2025 Jan 14;18(1):100-106. doi: 10.1159/000542915. eCollection 2025 Jan-Dec.
6
EPO-Mimetic Peptide Pegmolesatide Therapy for Pure Red Cell Aplasia in a Patient with Non-dialysis-dependent Type 1 Diabetic Nephropathy: A Case Report.促红细胞生成素模拟肽培格莫萨特治疗非透析依赖型1型糖尿病肾病患者纯红细胞再生障碍性贫血:一例报告
Kidney Med. 2024 Dec 15;7(2):100947. doi: 10.1016/j.xkme.2024.100947. eCollection 2025 Feb.
7
Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes.来那度胺诱导的纯红细胞再生障碍与红细胞上 MHC-I 分子的表达升高有关。
Nat Commun. 2024 Nov 22;15(1):10131. doi: 10.1038/s41467-024-54571-w.
8
First Reported Case of Pure Red Cell Aplasia Related to Sotorasib.首例与索托拉西布相关的纯红细胞再生障碍性贫血病例报告
Intern Med. 2025 Apr 1;64(7):1089-1092. doi: 10.2169/internalmedicine.3961-24. Epub 2024 Sep 4.
9
Thrombocytosis and megakaryocyte changes associated with PRCA.与纯红细胞再生障碍性贫血相关的血小板增多症和巨核细胞变化。
Blood Adv. 2024 Jun 25;8(12):3058-3062. doi: 10.1182/bloodadvances.2023012309.
10
Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.吉特替尼联合维奈托克和阿扎胞苷治疗异基因造血干细胞移植后并发纯红细胞再生障碍的复发急性髓系白血病:一例报告。
Ann Hematol. 2024 May;103(5):1775-1777. doi: 10.1007/s00277-024-05714-y. Epub 2024 Apr 1.

本文引用的文献

1
Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group.胸腺瘤相关纯红细胞再生障碍性贫血免疫抑制治疗后的长期反应及结局:日本PRCA协作研究组的一项全国性队列研究
Haematologica. 2008 Jan;93(1):27-33. doi: 10.3324/haematol.11655.
2
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model.血红蛋白与促红细胞生成素在免疫上不同,并且在大鼠纯红细胞再生障碍模型中可纠正由抗促红细胞生成素抗体诱导的贫血。
Exp Hematol. 2007 Aug;35(8):1201-8. doi: 10.1016/j.exphem.2007.05.007.
3
Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.接受环孢素A治疗的获得性原发性特发性纯红细胞再生障碍性贫血患者的长期预后。日本针对纯红细胞再生障碍性贫血协作研究组开展的一项全国性队列研究。
Haematologica. 2007 Aug;92(8):1021-8. doi: 10.3324/haematol.11192. Epub 2007 Jul 20.
4
Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan.抗胸腺细胞球蛋白联合环孢素A加或不加粒细胞集落刺激因子治疗成人重型再生障碍性贫血:日本一项多中心随机研究
Blood. 2007 Sep 15;110(6):1756-61. doi: 10.1182/blood-2006-11-050526. Epub 2007 May 25.
5
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.利妥昔单抗治疗自身免疫性中性粒细胞减少症和纯红细胞再生障碍性贫血缺乏临床疗效:对其病理生理学的启示。
Ann Hematol. 2007 Mar;86(3):191-7. doi: 10.1007/s00277-006-0202-5. Epub 2006 Nov 23.
6
Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience.胸腺瘤相关的纯红细胞再生障碍:来自一家机构50年经验的临床见解
Br J Haematol. 2006 Nov;135(3):405-7. doi: 10.1111/j.1365-2141.2006.06295.x.
7
T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.T细胞大颗粒淋巴细胞白血病:29例患者的治疗报告及文献综述
Cancer. 2006 Aug 1;107(3):570-8. doi: 10.1002/cncr.22032.
8
Current concepts in the pathophysiology and treatment of aplastic anemia.再生障碍性贫血病理生理学与治疗的当前概念
Blood. 2006 Oct 15;108(8):2509-19. doi: 10.1182/blood-2006-03-010777. Epub 2006 Jun 15.
9
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.在一项针对健康志愿者的1期双盲、安慰剂对照、剂量递增研究中,对新型促红细胞生成剂Hematide的安全性和药效学进行评估。
Blood. 2006 Sep 15;108(6):1830-4. doi: 10.1182/blood-2006-04-015818. Epub 2006 May 23.
10
Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature.利妥昔单抗治疗B细胞淋巴增殖性疾病所致纯红细胞再生障碍:2例报告并文献复习
Leuk Res. 2006 Jan;30(1):109-14. doi: 10.1016/j.leukres.2005.05.017. Epub 2005 Jul 25.

获得性纯红细胞再生障碍性贫血:治疗的最新综述

Acquired pure red cell aplasia: updated review of treatment.

作者信息

Sawada Kenichi, Fujishima Naohito, Hirokawa Makoto

机构信息

Department of Internal Medicine III, Division of Haematology, Akita University Graduate School of Medicine, Akita, Japan.

出版信息

Br J Haematol. 2008 Aug;142(4):505-14. doi: 10.1111/j.1365-2141.2008.07216.x. Epub 2008 May 28.

DOI:10.1111/j.1365-2141.2008.07216.x
PMID:18510682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2592349/
Abstract

Pure red cell aplasia (PRCA) is a syndrome characterized by a severe normocytic anaemia, reticulocytopenia, and absence of erythroblasts from an otherwise normal bone marrow. Primary PRCA, or secondary PRCA which has not responded to treatment of the underlying disease, is treated as an immunologically-mediated disease. Although vigorous immunosuppressive treatments induce and maintain remissions in a majority of patients, they carry an increased risk of serious complications. Corticosteroids were used in the treatment of PRCA and this has been considered the treatment of first choice although relapse is not uncommon. Cyclosporine A (CsA) has become established as one of the leading drugs for treatment of PRCA. However, common concerns have been the number of patients treated with CsA who achieve sustained remissions and the number that relapse. This article reviews the current status of CsA therapy and compares it to other treatments for diverse PRCAs.

摘要

纯红细胞再生障碍性贫血(PRCA)是一种以严重正细胞性贫血、网织红细胞减少以及正常骨髓中无成红细胞为特征的综合征。原发性PRCA或对基础疾病治疗无反应的继发性PRCA被视为免疫介导性疾病。尽管积极的免疫抑制治疗可使大多数患者诱导缓解并维持缓解状态,但它们会增加严重并发症的风险。皮质类固醇曾用于PRCA的治疗,这一直被视为首选治疗方法,尽管复发并不罕见。环孢素A(CsA)已成为治疗PRCA的主要药物之一。然而,人们普遍关注的是接受CsA治疗并实现持续缓解的患者数量以及复发的患者数量。本文综述了CsA治疗的现状,并将其与其他治疗不同类型PRCA的方法进行比较。